Yahoo Finance7d
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...
Investing7d
MAIA Biotechnology reports promising THIO trial results for NSCLC
The trial evaluates THIO, a telomere-targeting agent, in combination with Regeneron (NASDAQ:REGN)'s cemiplimab, an immune checkpoint inhibitor, in patients who have not responded to at least two ...